At the 2026 ASCO Genitourinary Cancers Symposium, Fred Saad, MD, presented encouraging phase 1 data evaluating the ...
CD25 expression has long been recognized as an adverse prognostic marker in acute leukemias including acute myeloid leukemia ...
Around the same time, LITESPARK-022 further positioned the drug in the second-line setting in combination strategies.
The FDA has granted Fast Track Designation to AKY-1189 (actinium-225; 225 Ac) a potent alpha-emitting radioisotope in the ...
A genome-wide cfDNA methylation enrichment method (cfMeDIP-seq) enables response monitoring using plasma alone, avoiding ...
The current research frontier in blastic plasmacytoid dendritic cell neoplasm (BPDCN) is moving toward combination triplet therapies. Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, explores ...
In this opening segment, Dr. Marwan Fakih and Dr. Richard Kim outline the current epidemiology, biology, and therapeutic ...
Treatment options for pancreatic neuroendocrine tumors (PNETs) have expanded considerably based on data from pivotal trials such as RADIANT-3 (NCT00510068), 1 Study A6181111 (NCT0 ...
Using the best medication available in the frontline setting of RCC leads to optimal results. David Braun, MD, of the Yale School of Medicine explores the strategic tension between immediate, ...
TTLC 2026 spotlights next-gen lung cancer therapies, co-mutation strategies, and ctDNA monitoring—insights beyond CME for what’s coming next. At the 2026 IASLC Targeted Therapies in Lung Cancer (TTLC) ...
FDA PMA establishes Claire as the first AI-integrated imaging device indicated for real-time intraoperative margin assessment during breast-conserving surgery. Re-excision remains ~20% nationally, ...
CD123 is universally and highly expressed on BPDCN cells. Because CD123 expression is significantly lower on normal hematopoietic stem cells, it provides a distinct "therapeutic window," allowing for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results